Folinic acid [58-05-9]
Cat# T24403-100mg
Size : 100mg
Marca : TargetMol
Folinic acid
(Synonyms: Leucovorin, HSDB 6544) Copy Product Info
Folinic acid (Leucovorin) is a biofolate used in the treatment of methotrexate (MTX) toxicity reduction and as an adjuvant therapy for colon cancer.
Cas No. 58-05-9
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.76%
Appearance:Solid
Color:White
COA HNMR LCMS
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Folinic acid (Leucovorin) is a biofolate used in the treatment of methotrexate (MTX) toxicity reduction and as an adjuvant therapy for colon cancer. |
| In vitro | Methotrexate (MTX) alone induces a concentration-dependent increase in the percentage of micronucleated binucleated cells (MNBN) and abnormal cells (Abs). As the concentration of MTX increases, the nuclear division index (NDI) decreases. Similarly, the mitotic index (MI) also decreases at all tested concentrations of MTX. The addition of 50 μg/mL folinic acid significantly reduces the % MNBN (40-68%) and % Abs (36-77%). In the presence of 5 μg/mL folinic acid, inhibitory effects are observed as well (MNBN from 12% to 54%, Abs from 20% to 61%)[2]. |
| In vivo | Treatment with folinic acid (7.0 mg/kg; intraperitoneal injection; every other day; for 3 weeks) appears to reverse the growth inhibition induced by Methotrexate (MTX) administration in young male Balb/c mice. Long-term MTX administration is known to inhibit skeletal growth in mice[1]. |
| Synonyms | Leucovorin, HSDB 6544 |
| Molecular Weight | 473.44 |
| Formula | C20H23N7O7 |
| Cas No. | 58-05-9 |
| Smiles | Nc1nc2NCC(CNc3ccc(cc3)C(=O)NC(CCC(O)=O)C(O)=O)N(C=O)c2c(=O)[nH]1 |
| Relative Density. | 1.4485 g/cm3 (Estimated) |
| Storage | Keep away from direct sunlight,The compound is unstable in solution. Please use soon,Store under nitrogen, Powder: -20°C for 3 years Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 260 mg/mL (549.17 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.22 mM), The compound is unstable in solution, please use soon. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||